Aktienanalyse zu KALA BIO Inc (KALA)KALAKALA BIO Inc

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

KALA BIO Inc is not a good buy right now due to its significantly low price and poor financial performance. The current price is $0.16, which is a staggering 99.50% decline year-to-date. Additionally, the company has a very low RSI of 26.603, indicating it is oversold, but this does not guarantee a recovery. The forward P/E ratio is 0, suggesting no expected earnings growth, and the company has reported substantial losses, with a net income of -$8,175,000 in Q4 2024. The main risk is its high volatility, as evidenced by a 52-week high of $95.50 and a low of $0.11, which reflects extreme market uncertainty.

4 analysts cover KALA: 4 rate it Buy, 0 Hold and 0 Sell.